Loading...
•
Jun 30, 2021
STERIS Q1 2022 Earnings Report
Reported a strong start to fiscal year 2022 with revenue increase and Cantel Medical integration on track.
Key Takeaways
STERIS plc reported a strong first quarter for fiscal year 2022, with revenue increasing by 45% to $968.4 million. Constant currency organic revenue increased by 21%. The company is making good progress with the integration of Cantel Medical and has updated its outlook for fiscal 2022 to reflect better than anticipated performance across the company.
First quarter revenue increased 45% as reported; 21% constant currency organic.
Cantel Medical integration is on track.
Company increased outlook for fiscal year 2022.
Company raised quarterly dividend.
Revenue by Segment
Forward Guidance
STERIS now expects as reported revenue of approximately $4.6 billion. Constant currency organic revenue growth is now expected to be in the range of 10-11% for fiscal 2022. Adjusted earnings per diluted share are anticipated to be in the range of $7.60 - $7.85. Free cash flow for fiscal 2022 is now expected to be approximately $400 million.
Positive Outlook
- As reported revenue of approximately $4.6 billion
- Constant currency organic revenue growth is now expected to be in the range of 10-11% for fiscal 2022
- Currency movements are anticipated to be favorable to revenue by approximately $30 million for fiscal 2022.
- Adjusted earnings per diluted share are anticipated to be in the range of $7.60 - $7.85
- Free cash flow for fiscal 2022 is now expected to be approximately $400 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...